Singapore, Dec 16: Zuellig Pharma, one of Asia’s leading healthcare solutions providers, has expanded its strategic partnership with Danish biopharmaceutical company H. Lundbeck A/S to strengthen the commercialization of neuro-psychiatric health solutions across key Asian markets.
Under the expanded agreement, Zuellig Pharma will act as an agency partner to commercialize Lundbeck’s portfolio of brain health products—including well-known brands such as Lexapro®, Brintellix® and Cipralex®—in Indonesia, Malaysia, the Philippines, and Singapore. The collaboration builds on an existing distribution arrangement under which Zuellig Pharma already handled the distribution of Lundbeck’s products in these markets. The partnership has also been extended to Taiwan.
As part of the enhanced collaboration, Zuellig Pharma will provide end-to-end commercialization support, covering marketing and commercial execution, market access, distribution and supply chain management, medical information services, regulatory and quality support, and pharmacovigilance.
The companies said the expanded partnership leverages Zuellig Pharma’s extensive regional network and deep local-market expertise, enabling Lundbeck to strengthen patient access to treatments for neurological and psychiatric conditions across Asia.
“We value our long-standing collaboration with Lundbeck and remain committed to improving access to neuro-psychiatric health solutions in Asia,” said John Graham, CEO of Zuellig Pharma. “Our strong regional network, expertise, and understanding of local regulatory environments will be critical in ensuring continuity of care and expanding access to these important medicines.”
The move comes amid growing awareness and diagnosis of mental health and neurological disorders across Asia, where access to specialised treatments remains uneven. By combining Lundbeck’s focus on brain health with Zuellig Pharma’s integrated healthcare capabilities, the partnership aims to address unmet needs and support more consistent delivery of care in the region.